New-Onset Uveitis Possibly Caused by Secukinumab in a 47-Year-Old Male Patient with Long-Standing Ankylosing Spondylitis

Secukinumab, “an IL-17 antagonist”, is one of the biological agents used to treat active ankylosing spondylitis (AS). Although it has been proven that certain agents are linked with a paradoxical increase in uveitis, there are limited data on whether secukinumab has this effect or not. We report a c...

Descripción completa

Detalles Bibliográficos
Autores principales: Nadwi, Huda, Janaini, Murad, Zammo, Mohammed, Cheikh, Mohamed, Almoallim, Hani
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7415454/
https://www.ncbi.nlm.nih.gov/pubmed/32801946
http://dx.doi.org/10.2147/IMCRJ.S265812

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7415454/
https://www.ncbi.nlm.nih.gov/pubmed/32801946
http://dx.doi.org/10.2147/IMCRJ.S265812

Ejemplares similares